Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Hong Ki MinHae-Rim KimSang-Heon LeeKichul ShinHyoun-Ah KimSung-Hwan ParkSeung Ki KwokPublished in: Clinical rheumatology (2021)
Long-term use of bDMARDs and tsDMARDs is relatively safe with regard to lipid profile, AIP, and the occurrence of dyslipidemia in RA patients. Key Points • The use of bDMARDs and tsDMARDs did not increase the risk of dyslipidemia than cDMARDs use in patients with RA. • AIP was comparable between bDMARDs user, tsDMARDs user, and cDMARDs user group in 4-year follow-up data. • Based on the present study, the long-term use of bDMARDs or tsDMARDs did not significantly deteriorate atherogenic lipid profile nor an increased risk of dyslipidemia in patients with RA.
Keyphrases
- disease activity
- rheumatoid arthritis patients
- rheumatoid arthritis
- end stage renal disease
- systemic lupus erythematosus
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- risk assessment
- chronic kidney disease
- juvenile idiopathic arthritis
- peritoneal dialysis
- prognostic factors
- interstitial lung disease
- patient reported outcomes